Close Menu

You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.

Home › Business, Policy & Funding › Business News › Inova Decides to End PGx Test Offerings in Response to FDA Warning Letter

Inova Decides to End PGx Test Offerings in Response to FDA Warning Letter

Apr 15, 2019
|
staff reporter

This article has been updated with a statement from the Clinical Pharmacogenetics Implementation Consortium.

NEW YORK (GenomeWeb) – Inova Health System has decided to completely stop performing its suite of pharmacogenetic tests in response to a US Food and Drug Administration warning letter.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Oct
09
Featured Webinar

Navigating the FDA's EUA Process for Diagnostics in the Present and Future: A Stakeholder Panel Discussion

Sponsored by
PerkinElmer

As cases of COVID-19 continued to grow this spring and summer in the US, so too did the number of Emergency Use Authorizations from the FDA for clinical diagnostic tests aimed at detecting current and past infections.

What's Popular?

In Regulatory News & FDA Approvals

  1. Roche SARS-CoV-2 Lateral Flow Antigen Test Could Meet Significant Demand

    Premium

  2. Cepheid Multiplex SARS-CoV-2, Flu, RSV Test Nabs FDA Emergency Use Authorization

  3. BGI Genomics Gets CE Mark for Multiplexed SARS-CoV-2, Influenza Tests

  4. FDA Revises Emergency Use Authorization for Abbott Point-of-Care SARS-CoV-2 Test

  5. FDA Grants Emergency Use Authorization for Jiangsu Well Biotech Coronavirus Antibody Test

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.